Skip to main content
. 2020 Mar 14;9(1):571–581. doi: 10.1080/22221751.2020.1738278

Figure 3.

Figure 3.

Anti-MERTK antibodies or soluble MERTK ectodomain blocks CSFV infection in a dose-dependent manner. (A and B) Antibodies against MERTK reduce CSFV infection. PK-15 cells were pretreated with antibodies against MERTK or isotype IgG at indicated concentrations for 30 min, and then infected with CSFV-SM (MOI=0.01) in the continuous presence of the antibodies. The viral genome copies (A) and progeny viral titers (B) were measured at 48 hpi. (C) Identification of purified MERTKED-His and E2ED-His proteins stained with Coomassie blue. (D) MERTKED-His has no effects on the cell viabilities. (E and F) Soluble MERTKED-His reduces CSFV infection. CSFV-SM (MOI=0.01) was incubated with the indicated concentrations of soluble MERTKED-His or BSA for 30 min at room temperature, and then infected with PK-15 cells. The viral genome copies (E) and progeny viral titers (F) were measured at 48 hpi. (G and H) Anti-MERTK antibodies reduce CSFV-HLJ infection in a dose-dependent manner. PK-15 cells were infected with CSFV-HLJ (MOI=0.01) after incubation with anti-MERTK antibodies for 30 min. The viral genome copies (G) and progeny viral titers (H) were examined at 48 hpi. Means ± standard deviations (SD) of three technical replicates are shown. **, P < 0.01; ***, P < 0.001.